UPDATE : Friday, July 20, 2018
상단여백
FDA to review Samsung Bioepis’ trastuzumab biosimilar by Lee Han-soo 2017-12-20 14:37
Nature Cell expects to receive conditional approval for Jointstem by Lee Han-soo 2017-12-19 18:22
‘Celltrion’s annual revenue to top ₩3 trillion in 5 years’ by Nam Doo-hyun 2017-12-18 15:55
Samsung Bioepis, Daewoong sign exclusive supply contract for Samfenet by Lee Han-soo 2017-12-18 10:59
Corestem’s NeuroNata-R marks increase in foreign patients by Lee Han-soo 2017-12-15 16:22
라인
FDA approves Pfizer’s Remicade biosimilar by Lee Han-soo 2017-12-14 17:16
Samsung BioLogics’ 2nd factory gets European approval by Lee Han-soo 2017-12-14 10:52
‘Surge of gene-therapy providing hospitals to benefit Invossa’ by Nam Doo-hyun 2017-12-12 15:59
PCL shares rise despite regulator’s warning by Nam Doo-hyun 2017-12-12 11:02
Oscotec shares rebound on launch of US clinical trial by Nam Doo-hyun 2017-12-11 15:50
라인
ToolGen’s shares jump on gene therapy market expectations by Nam Doo-hyun 2017-12-11 15:16
MGmed to run world’s 1st postmortem DNA bank by Marian Chu 2017-12-08 17:11
Toolgen wins German utility model for gene editing tool by Lee Han-soo 2017-12-08 16:56
Celltrion seeks to shift to main bourse by Lee Han-soo 2017-12-07 11:25
Medipost wins patent for Cartistem in Europe by Lee Han-soo 2017-12-06 13:15
라인
MGmed emerges as largest shareholder of UK bio venture by Marian Chu 2017-12-06 13:00
Kolon Life Science confident to make Invossa global blockbuster by Nam Doo-hyun 2017-12-06 09:30
ViroMed starts trial on VM202’s effect on peripheral artery disease by Lee Han-soo 2017-12-05 15:40
Shares of biotech firms, listed with ‘exceptional techs,’ rise above offer price by Nam Doo-hyun 2017-12-05 14:38
Sewon seeks p3 clinical trials for cartilage cell therapy in Japan by Lee Han-soo 2017-12-04 16:17
여백
여백
여백
Back to Top